Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q2 2023 Earnings Presentation
14 slides from Bactiguard Holding Ab's earnings presentation, Jul 18, 2023
Slide 1: Interim Report Q2 2023 presentation
Interim Report Q2 2023 presentation Tuesday July 18, 2023 Thomas von Koch, interim CEO
Slide 2: Strategy of bolstering Licensing and US go-to-market stays firm
Interim Report Q2 2023: Strategy of bolstering Licensing and US go-to- market stays firm
Slide 3: Opportunities behind critical global healthcare trends
Opportunities behind critical global healthcare trends “not a question of if, it’s a question of when” The issues The USD 80bn market opportunity • Rise of infections, increased antibiotics use and development Orthopedics 40 of multi-resistant bacteria a threat to global health and modern medicine •
Slide 4: Preventing infections – a top-priority in US healthcare
Preventing infections – a top-priority in US healthcare Did you know that… 50% of patients in American emergency hospitals take antibiotics preventively. Even so, in these hospitals… • 3% have HAI • nearly 700,000 contract HAI (of which around 70,000 die) HAI and frequent use of antibiotics feed mul
Slide 5: Well-needed clean up to focus on our growth strategy
“Well-needed clean up to focus on our growth strategy” One-time adjustments of 42 MSEK announced on July 7, 2023 Write-down of inventories – stock of devices and raw materials, outdated or close to outdated 15% 15% Other structural changes within the organization 70% Accounts receivable overdue and
Slide 6: Financials Q2 2023 (Q2 2022) and key events
Financials Q2 2023 (Q2 2022) and key events Strategy of bolstering Licensing and US go-to-market stays firm Revenues EBITDA Net Loss Operating cash flow 51 (60) MSEK -55.7 (-3.8) MSEK -64.5 (-13.7) MSEK -20.4 (-1.1) MSEK Includes -42 MSEK one-time Key events Q2 • Regulatory approval of ZNN Bactiguar
Slide 7: Financial overview
Financial overview Amounts in MSEK 2023 2022 2023 2023 • Total revenue decrease 15% Apr-Jun Apr-Jun Jan-Jun Jan-Jun ‒ License -31% Total revenues 51.2 59.9 112.4 115.1 ‒ BPP +25% - License 24.8 36.2 64.2 72.6 - BPP 19.4 15.6 35.6 30.9 • Investment phase related to EBITDA -55.7 -3.8 -62.3 -7.8 growth
Slide 8: Rolling 12-months revenues
Rolling 12-months revenues Long-term business MSEK • revenues transform over time 80 250 Recurring license revenues 60 (blue) 200 40 • key driver BD and initial contributions from Zimmer 150 20 Biomet (trauma) 100 0 Non-recurring license revenues (yellow) -20 50 • Zimmer Biomet (broader -40 portfoli
Slide 9: Q2 2023 highlights – Licensing business
Q2 2023 highlights – Licensing business Recurring revenues Non-recurring revenues Revenues Q2 2023 Revenues Q2 2023 18.5 (29.0) MSEK 6.3 (7.2) MSEK -36%* -13%* Orthopedics (trauma) Orthopedics (broader portfolio) • Progress according to plan • Progress according to plan • Largest license partner • Z
Slide 10: Q2 2023 highlights – BPP
Q2 2023 highlights – BPP BPP (Bactiguard Product Portfolio) Revenues Q2 2023 19.4 (15.6) MSEK +25%* • Strong sales in May and June • Continued focus on profitability and operational excellence • Study comparing Bactiguard’s coated central venous catheters with non- coated launched • Bactiguard Wound
Slide 11: Recap of key priorities 2023
Recap of key priorities 2023 Continued focus on Licensing and US go-to-market strategy, and BPP operational excellence Strengthen Technology – BPP – license business – drive and develop profitability and operational current and new partners coating, current and new excellence US go-to-market Continu
Slide 12: Drivers to deliver growth and profitability
Drivers to deliver growth and profitability “not a question of if, it’s a question of when” M&A Financial targets 2026 Revenues >1 billion SEK EBITDA >400 million SEK Illustrative * Today Orthopedics (broader portfolio) Existing license customers Orthopedics (trauma) 12 * Currently a global developm
Slide 13: Questions & Answers
Questions & Answers Interim Report Q2 2023 Thomas von Koch Carin Jakobson interim CEO CFO
Slide 14: Q&A
Q&A Q&A to champion a healthier world by preventing infections 14